{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:07:31Z","timestamp":1787728051499,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C9474\/A18362"],"award-info":[{"award-number":["C9474\/A18362"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.canep.2019.02.014","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T18:18:43Z","timestamp":1551723523000},"page":"236-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK\u2019s population-based Haematological Malignancy Research Network"],"prefix":"10.1016","volume":"59","author":[{"given":"Eleanor","family":"Kane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-966X","authenticated-orcid":false,"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Patmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-3704","authenticated-orcid":false,"given":"Eve","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2019.02.014_bib0005","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2019.02.014_bib0010","article-title":"US lymphoid malignancy statistics by World Health Organization subtypes","volume":"2016","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canep.2019.02.014_bib0015","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2019.02.014_bib0020","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017"},{"key":"10.1016\/j.canep.2019.02.014_bib0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","article-title":"Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces?","volume":"24","author":"Baecklund","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canep.2019.02.014_bib0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ijc.25680","article-title":"Non-Hodgkin lymphoma and autoimmunity: does gender matter?","volume":"129","author":"Ansell","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2019.02.014_bib0035","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.24287","article-title":"Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies","volume":"125","author":"Anderson","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2019.02.014_bib0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","article-title":"Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Cerhan","year":"2014","journal-title":"J. Natl. Cancer Inst. Monographs"},{"key":"10.1016\/j.canep.2019.02.014_bib0045","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/art.40017","article-title":"Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased?","volume":"69","author":"Hellgren","year":"2017","journal-title":"Arthrit. Rheumatol. (Hoboken, N. J.)"},{"key":"10.1016\/j.canep.2019.02.014_bib0050","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","volume":"111","author":"Ekstr\u00f6m Smedby","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canep.2019.02.014_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2525","article-title":"Rheumatoid arthritis and lymphoma: incidence, pathogenesis, biology, and outcome","author":"Klein","year":"2018","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.canep.2019.02.014_bib0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2141.2008.07011.x","article-title":"Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis","volume":"141","author":"Baecklund","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2019.02.014_bib0065","article-title":"Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK\u2019s population-based Haematological Malignancy Research Network","author":"Painter","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2019.02.014_bib0070","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2019.02.014_bib0075","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.clml.2017.11.009","article-title":"Characterizing autoimmune disease-associated diffuse large B-cell lymphoma in a SEER-Medicare cohort","volume":"18","author":"Koff","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.canep.2019.02.014_bib0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/hon.2498","article-title":"Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma","volume":"36","author":"Kleinstern","year":"2018","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.canep.2019.02.014_bib0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-018-0105-4","article-title":"History of autoimmune conditions and lymphoma prognosis","volume":"8","author":"Kleinstern","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canep.2019.02.014_bib0090","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO.2005.04.6227","article-title":"Prospective study of survival outcomes in Non-Hodgkin\u2019s lymphoma patients with rheumatoid arthritis","volume":"24","author":"Mikuls","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2019.02.014_bib0095","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2009.08010.x","article-title":"The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research","volume":"148","author":"Smith","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2019.02.014_bib0100","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyy044","article-title":"Cohort profile: the Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort","volume":"47","author":"Smith","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.canep.2019.02.014_bib0105","series-title":"Cancer Reform Strategy","author":"Department of Health","year":"2007"},{"key":"10.1016\/j.canep.2019.02.014_bib0110","series-title":"Improving Outcomes: A Strategy for Cancer","author":"Department of Health","year":"2011"},{"key":"10.1016\/j.canep.2019.02.014_bib0115","series-title":"Addendum to Haematological Cancers: Improving Outcomes (Update)","author":"National Collaborating Centre for Cancer (UK)","year":"2016"},{"key":"10.1016\/j.canep.2019.02.014_bib0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.canep.2019.02.014_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055895","article-title":"A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma","volume":"8","author":"Care","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canep.2019.02.014_bib0130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.12045","article-title":"Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome","volume":"159","author":"Barrans","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2019.02.014_bib0135","series-title":"Rheumatoid Arthritis in Adults: Management | Guidance and Guidelines | NICE","author":"National Insitute for Health Care Excellence","year":"2019"},{"key":"10.1016\/j.canep.2019.02.014_bib0140","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/rheumatology\/kex375","article-title":"The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren\u2019s Syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.canep.2019.02.014_bib0145","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.2517-6161.1968.tb00759.x","article-title":"A simplified Monte Carlo significance test procedure","volume":"30","author":"Hope","year":"1968","journal-title":"J. R. Stat. Soc."},{"key":"10.1016\/j.canep.2019.02.014_bib0150","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","article-title":"Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Morton","year":"2014","journal-title":"J. Natl. Cancer Inst. Monographs"},{"key":"10.1016\/j.canep.2019.02.014_bib0155","article-title":"Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies","volume":"9","author":"Shen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canep.2019.02.014_bib0160","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.canep.2019.02.014_bib0165","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.canep.2019.02.014_bib0170","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.31407","article-title":"Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions","author":"Calip","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2019.02.014_bib0175","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jncimonographs\/lgu011","article-title":"Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Bracci","year":"2014","journal-title":"J. Natl. Cancer Inst. Monographs"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782119300128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782119300128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:25:33Z","timestamp":1761801933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782119300128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":35,"alternative-id":["S1877782119300128"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2019.02.014","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK\u2019s population-based Haematological Malignancy Research Network","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2019.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}